Patent · US Active

Expression constructs expressing Prkag3

US7858369B2 · kind B2 · utility

0Cited by

4References

8Claims

0Family size

Assignee

Arexis AB · SE

Inventors

Leif Andersson · Finspång, SE
Stefan Marklund · Uppsala, SE

Key dates

Filing date	May 4, 2007
Grant date	Dec 28, 2010
Priority date	—
Expiry date	Nov 24, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/008
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Transgenic non-human animals that express the γ3 subunit of PRKAG are described, as well as methods of using the transgenic non-human animals as models for improving treatment, prevention, or diagnosis of diseases related to energy metabolism, including obesity, dyslipidemia, insulin resistance syndrome, and type 2 diabetes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.